Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Aug 2018

Song Jiangdian, Shi Jingyun, Dong Di, Fang Mengjie, Zhong Wenzhao, Wang Kun, Wu Ning, Huang Yanqi, Liu Zhenyu, Cheng Yue, Gan Yuncui, Zhou Yongzhao, Zhou Ping, Chen Bojiang, Liang Changhong, Liu Zaiyi, Li Weimin, Tian Jie

Abstract excerpt

Purpose: We established a CT-derived approach to achieve accurate progression-free survival (PFS) prediction to EGFR tyrosine kinase inhibitors (TKI) therapy in multicenter, stage IV EGFR-mutated non-small cell lung cancer (NSCLC) patients.Experimental Design: A total of 1,032 CT-based phenotypic characteristics were extracted according to the intensity, shape, and texture of NSCLC pretherapy images. On the basis...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Gefitinib

Share to Neoplasm Staging

Share to Positron Emission Tomography Computed Tomography

Share to Progression-Free Survival

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 29563137
DOI: 10.1158/1078-0432.CCR-17-2507

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy.PMID 29563137Read ↗

A radiomics-based deep learning approach to predict progression free-survival after tyrosine kinase inhibitor therapy in non-small cell lung cancer.Semantic proximity Read ↗

Radiomic and clinical predictors of epidermal growth factor receptor mutation in stage IA non-small cell lung cancer.Semantic proximity Read ↗

Multimodal prediction of tyrosine kinase inhibitors therapy outcomes in advanced EGFR-mutated NSCLC patients.Semantic proximity Read ↗

Integrated CT-derived radiomics for predicting ctDNA status and prognosis in resectable non-small cell lung cancerSemantic proximity Read ↗

The Potential of Radiomics Nomogram in Non-invasively Prediction of Epidermal Growth Factor Receptor Mutation Status and Subtypes in Lung AdenocarcinomaSemantic proximity Read ↗

Radiomics combined with clinical characteristics predicted the progression-free survival time in first-line targeted therapy for advanced non-small cell lung cancer with EGFR mutationSemantic proximity Read ↗

Radiomics combined with clinical characteristics predicted the progression-free survival time in first-line targeted therapy for advanced non-small cell lung cancer with EGFR mutation.Semantic proximity Read ↗

CT delta-radiomics for identification of advanced EGFR-Mutated lung adenocarcinoma Sensitive to Therapies Targeting EGFR PathwaySemantic proximity Read ↗

Non-invasive decision support for NSCLC treatment using PET/CT radiomics.Semantic proximity Read ↗

The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

Towards a Survival Risk Prediction Model for Metastatic NSCLC Patients on Durvalumab Using Whole-Lung CT RadiomicsSemantic proximity Read ↗

EfficientNet-Based System for Detecting EGFR-Mutant Status and Predicting Prognosis of Tyrosine Kinase Inhibitors in Patients with NSCLC.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.